TMB, defined as the number of somatic mutations per megabase of interrogated genomic sequence, is believed to be a key driver in the generation of immunogenic neopeptides displayed on major histocompatibility complexes (MHC) on the tumor cell surface that influence patient response to ICIs (40). The gene discussed is HLA-C; the disease is neoplasm.